Ascendis Pharma AS (NAS:ASND)
$ 137.5 -2.81 (-2%) Market Cap: 8.39 Bil Enterprise Value: 8.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Q4 2019 Ascendis Pharma A/S Earnings Call Transcript

Apr 01, 2020 / 08:30PM GMT
Release Date Price: $113 (+0.35%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the full year 2019 financial results and business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Scott Smith, Senior Vice President and Chief Financial Officer at Ascendis Pharma. Please go ahead.

Scott T. Smith;S;CFO;Senior VP
Ascendis Pharma A

/-&

Thank you, operator. Thank you, everyone, for joining our full year 2019 financial results conference call today. I'm Scott Smith, Chief Financial Officer of Ascendis. Joining me on today's call is Jan Mikkelsen, President and Chief Executive Officer; Tom Larson, Chief Commercial Officer; Dr. Juha Punnonen, Head of Oncology; and Dr. Dana Pizzuti, Head of Development Operations.

Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot